CD8A and neoplasm: For larger tumors (200–400 mm3), 5 × 105 CD8+ TCROT-I cells were transferred, followed by anti–PD-1 infusion 12 days later, when tumors began to regrow, we observed that adoptive transfer of decitabine-primed T cells plus anti–PD-1 significantly restrained tumor growth compared with control T cells plus anti–PD-1 (Figure 1, E and F).